EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022

London (PRWEB) November 19, 2013

EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022

Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ systems, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ unfortunate with episodes of relapses and remissions. The disease has unpredictable natural course and high rates of morbidity and death The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements such as the characteristics of the population studied, sex, ethnicity, geographical locations, occupational factors, familial traits, time period involved, and the diagnostic criteria used. Lupus nephritis (LN) or lupus glomerulonephritis is a serious complication of SLE in which the kidneys are affected.

GlobalData epidemiologists utilized data from country-specific studies published in peer-reviewed journals and governmental documents to wage the age- and sex-specific prevalent cases of diagnosed SLE in the respective markets. The forecast methodology and disease diagnosis criteria were consistent crossways all of the 7MM to grant for a meaningful comparison among them. The SLE prevalent case forecast followed the 1982 American College of Rheumatology classification and the LN cases were segmented according to the WHO 1982 classification.

The report forecast that 2012 had 452,053 diagnosed prevalent cases of SLE in the 7MM, with approximately 60% of the diagnosed prevalent cases (265,562) in the US alone. GlobalData epidemiologists forecast that there will be 488,769 diagnosed prevalent cases of SLE in the 7MM by 2022, with an overall average annual growth rate (AGR) of 0.81% during the forecast period. GlobalDatas epidemiological forecast projected an increase in the diagnosed prevalent cases.

Scope

-The Systemic Lupus Erythematosus (SLE) EpiCast Report provides an overview of the risk factors and global trends for SLE for the seven major markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). GlobalData epidemiologists wage the 10-year epidemiological forecast of the diagnosed prevalent cases of SLE segmented by sex and age and the diagnosed prevalent cases of lupus nephritis (LN) for the 7MM. The prevalent cases of LN in the US, France, Germany, Italy, Spain, and UK are further segmented by severity class (Class IVI). The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Systemic Lupus Erythematosus EpiCast report will grant you to –

-Develop business strategies by understanding the trends shaping and driving the global SLE market.

-Quantify patient populations in the global SLE to improve product design, pricing, and launch plans.

-Organize income and marketing efforts by identifying the age groups, sex, and LN class that present the ideal opportunities for SLE therapeutics in apiece of the markets covered.

-Identify the percentage of LN prevalent cases in apiece severity class.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Introduction 7

2.1 Catalyst 7

3 Epidemiology 8

3.1 Disease Background 8

3.2 Risk Factors and Comorbidities 10

3.2.1 Women are at a higher risk of developing SLE than men 11

3.2.2 Caucasians are at lower risk of developing SLE than other ethnicities 12

3.2.3 Familial history has been associated with an increased risk of developing SLE 13

3.2.4 Certain occupational and environmental exposures trigger SLE 14

3.3 Global Trends 15

3.3.1 US 16

3.3.2 5EU 17

3.3.3 Nihon 20

3.4 Forecast Methodology 20

3.4.1 Sources Used 23

3.4.2 Sources Not Used 27

3.4.3 Forecast Assumptions and Methods 28

3.5 Epidemiological Forecast of SLE (20122022) 34

3.5.1 Diagnosed Prevalent Cases of SLE 34

3.5.2 Age-Specific Prevalent Cases of SLE 36

3.5.3 Sex-Specific Prevalent Cases of Diagnosed SLE 38

3.5.4 Age-Standardized Prevalence of SLE 40

3.5.5 Diagnosed Prevalent Cases of LN 41

3.5.6 Prevalent Cases of LN, Segmented by Class 43

3.6 Discussion 45

3.6.1 Conclusions on Epidemiology Trends 45

3.6.2 Limitations of the Analysis 46

3.6.3 Strengths of the Analysis 47

4 Appendix 49

4.1 Bibliography 49

4.2 About the Authors 54

4.2.1 Epidemiologist 54

4.2.2 Reviewers 54

4.2.3 Global Director of Epidemiology and Health Policy 56

4.2.4 Global Head of Healthcare 56

4.3 About GlobalData 57

4.4 About EpiCast 57

4.5 Disclaimer 58

1.1 List of Tables

Table 1: The 1982 Revised ARC Criteria For Classification of Systemic Lupus Erythematosus 9

Table 2: Risk Factors Associated with SLE 10

Table 3: World Health Organization Morphologic Classification of Lupus Nephritis (Modified in 1982) 21

Table 4: Sources of Prevalence Data Used in this Analysis 22

Table 5: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, Choose Years 20122022 35

Table 6: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37

Table 7: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, by Sex, N, Row (%), 2012 38

Table 8: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, Choose Years 20122022 42

Table 9: 6MM, Prevalent Cases in the Different Classes of LN, All Age, Both Sexes, N, Row (%), 2012 43

1.2 List of Figures

Figure 1: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, N, 20122022 35

Figure 2: 7MM, Prevalent Cases of Diagnosed SLE, by Age, Both Sexes, N, Row (%), 2012 37

Figure 3: 7MM, Prevalent Cases of Diagnosed SLE, All Ages, Both Sexes, 2012 39

Figure 4: 7MM, Age-Standardized Prevalence (%) of Diagnosed SLE, All Ages, by Sex, 2012 40

Figure 5: 7MM, Prevalent Cases of Diagnosed LN, All Ages, Both Sexes, N, 20122022 42

Figure 6: 6MM, Prevalent Cases of LN, by Class, All Ages, Both Sexes, 2012 44

Read the full report:

EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/epicast_report_systemic_lupus_erythematosus_epidemiology_forecast_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com







Find More Website Transparent Backgrounds Press Releases

EpiCast Report: Acute Ischemic Stroke – Epidemiology Forecast to 2022

London (PRWEB) November 28, 2013

EpiCast Report: Acute Ischemic Stroke – Epidemiology Forecast to 2022

Summary

Stroke occurs when the blood supply to the brain is blocked or interrupted, either by blood clots or ruptured blood vessels, depriving the brain of oxygen and nutrients, finally leading to the death of brain cells. Stroke is a major cause of death, morbidity, and long-term disability. To forecast the incident and prevalent cases of stroke in the 6MM, GlobalData epidemiologists selected studies that used the WHO definition of stroke: rapidly developing clinical signs of focal disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin. This definition excludes cases of transient ischemic attacks (TIAs), which are neurological deficits lasting less than 24 hours. This report also provides the incident cases of AIS segmented by the TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria subtypes and the proportion of recurrent cases of AIS out of the total cases of AIS (total cases of AIS = incident cases of first-ever AIS + recurrent cases of AIS) in these major markets.

GlobalData epidemiologists forecast that the incident cases of AIS in the 6MM will increase by 20.10% over the next decade, from 1.25 million cases in 2012 to 1.50 million cases in 2022, with more than 50% of the cases being in the US alone. The number of prevalent cases of AIS in the 6MM will increase by 18.6% over the forecast period, from 9.48 million cases in 2012 to 11.24 million cases in 2022. The substantially higher number of prevalent cases of AIS compared with the number of incident cases indicates that a higher proportion of stroke victims survive after the event for longer time periods. However, these stroke survivors will live with serious disabilities, making stroke a major burden for the affected individual and the entire healthcare system in apiece country.

Scope

-The Acute Ischemic Stroke (AIS) EpiCast Report provides an overview of the risk factors, comorbidities and the global epidemiological trends for AIS in the six major markets (6MM: US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast of the incident cases of AIS (all new cases of a first-ever AIS in a defined population in a specified time period) and the prevalent cases of AIS (all survivors of a first-ever AIS in a defined population at a specified point in time) segmented by sex and age (ages 2085+ years). This report also provides the incident cases of AIS segmented by the TOAST criteria subtypes and the proportion of recurrent cases of AIS out of the total cases of AIS.

-The AIS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

-The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

-Develop business strategies by understanding the trends shaping and driving the global AIS market.

-Quantify patient populations in the global AIS market to improve product design, pricing, and launch plans.

-Organize income and marketing efforts by identifying the age groups and sex that present the ideal opportunities for AIS therapeutics in apiece of the markets covered.

-Identify the percentage of apiece TOAST subtype among incident cases of AIS.

Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

3 Epidemiology 10

3.1 Disease Background 10

3.2 Risk Factors and Comorbidities 12

3.2.1 Atrial fibrillation increases the risk of AIS by as much as 15times 13

3.2.2 Hypertension elevates the risk of AIS by more than three times 14

3.2.3 The risk of AIS is nearly same in fat men and women 15

3.2.4 The risk of AIS increases with the duration of diabetes 15

3.2.5 Smoking increases the risk of AIS, which varies with the number of cigarettes smoked 16

3.2.6 Age is a strong predictor of AIS in both men and women 17

3.2.7 A family history of stroke, particularly a paternal history, is a strong predictor of stroke 18

3.2.8 Race/ethnicity is a strong predictor of AIS, and the risk varies with the different subtypes of AIS 19

3.3 Global Trends 20

3.3.1 US 22

3.3.2 France 26

3.3.3 Germany 28

3.3.4 Italy 30

3.3.5 Spain 32

3.3.6 UK 34

3.4 Forecast Methodology 36

3.4.1 Sources Used 40

3.4.2 Forecast Assumptions and Methods -Incident Cases of AIS 47

3.4.3 Forecast Assumptions and Methods-Prevalent Cases of AIS 51

3.4.4 Forecast Assumptions and Methods -AIS Recurrence Rate (%) 54

3.4.5 Sources Not Used 55

3.5 Epidemiological Forecast for AIS (2012-2022) 57

3.5.1 Incidence 57

3.5.2 Prevalence 65

3.5.3 AIS Recurrence Rate (%) 71

3.6 Discussion 72

3.6.1 Conclusions on Epidemiology Trends 72

3.6.2 Limitations of the Analysis 73

3.6.3 Strengths of the Analysis 74

4 Appendix 76

4.1 Bibliography 76

4.2 About the Authors 82

4.2.1 Epidemiologists 82

4.2.2 Reviewers 83

4.2.3 Global Director of Epidemiology and Health Policy 84

4.2.4 Global Head of Healthcare 84

4.3 About GlobalData 85

4.4 About EpiCast 85

4.5 Disclaimer 85

List of Tables

Table 1: TOAST Classification of Subtypes of AIS 11

Table 2: Risk Factors and Comorbidities for AIS 13

Table 3: Trends in the Age-Adjusted Incidence Rates of Stroke in the US (per 100,000 Population) 23

Table 4: Trend in the Crude Mortality Rate of Stroke in the US (per 100,000 Population), 1970-2008 24

Table 5: Trends in the Age-Adjusted Prevalence (%) of Stroke in the US, Ages ?18 Years, 2006-2010 25

Table 6: Trends in the Age-Adjusted Incidence Rates* of Stroke in France (per 100,000 Population) 26

Table 7: Trends in the Age-Specific Prevalence of Stroke (per 100,000 Population) in France, 2000 27

Table 8: Trends in the Crude Annual Incidence Rates of Stroke in Germany (per 100,000 Population) 28

Table 9: Trends in the Age-Specific Prevalence of Stroke (per 100,000 Population) in Germany, 2000 29

Table 10: Trends in the Total Crude Incidence Rates of Stroke in Italy (per 100,000 Population), All Ages 30

Table 11: Trends in the Age-Specific Prevalence of Stroke (per 100,000 Population) in Italy, 2000 31

Table 12: Trends in the Age-Adjusted Incidence Rates of Stroke in Spain (per 100,000 Population) 32

Table 13: Trends in the Age-Specific Prevalence of Stroke (per 100,000 Population) in Spain, 2000 33

Table 14: Trends in the Age-Adjusted Mortality Rate of Stroke in the UK (per 100,000 Population), 1981-2009 34

Table 15: Trends in the Prevalence (%) of Stroke in the UK, 1994-2011 35

Table 16:Sources of AIS Incidence Data 37

Table 17:Sources of AIS Prevalence Data 38

Table 18: Sources of AIS Recurrence (%) Data 39

Table 19: Sources of AIS Subtypes (%) Data 39

Table 20: 6MM, Incident Cases of AIS, Ages ?20 Years, Both Sexes, N, 2012-2022 57

Table 21: 6MM, Incident Cases of AIS, by Age, Both Sexes, N, Row (%), 2012 59

Table 22: 6MM, Incident Cases of AIS by Sex, Ages ?20 Years, N, Row (%), 2012 60

Table 23: 6MM, Incident Cases of AIS by Subtypes, Ages ?20 Years, Both Sexes, N (Row %), 2012 63

Table 24: 6MM, Prevalent Cases of AIS, Ages ?20 Years, Both Sexes, N, 2012-2022 65

Table 25:

WordPress SEO fine-tune by Meta SEO Pack from Poradnik Webmastera